IMTAKT HPLC COLUMN Unison UK-SILICA

Aqueous and Non-Aqueous, High-Performance Silica Column

IMTAKT HPLC COLUMN Unison UK-SILICA

FEATURES

Normal-phase column usable for both aqueous and non-aqueous systems

High-resolution 3μm silica

Wide range of column sizes: inner diameter 0.075 - 28mm / length 10-500mm

High-pressure resistance options
(HP: 500bar / 7,500psi / 50MPa, UP: 1,000bar / 15,000psi / 100MPa)

MAIN SPECIFICATIONS

Particle size: 3μm (Unison UK-Silica)
5μm (Unison US-Silica)
Base material: Fully porous high-purity silica gel
Pore size: 13nm
Ligand: Silica
Target molecular weight: Below 10kDa
pH range: pH 1-7
Maximum pressure: 250bar / 3,500psi / 25MPa
HP: 500bar / 7,500psi / 50MPa,
UP: 1,000bar / 15,000psi / 100MPa
USP Code: L3

Unison UK series with 3μm particles, which offers higher resolution compared to conventional 5μm columns, is also highly effective in normal-phase separations with a silica stationary phase. Unison UK-Silica was developed to achieve higher separation and faster analyses than traditional 5μm, 250mm silica columns. Unison UK-Silica can be used for both non-aqueous and aqueous normal-phase separations.

Unison UK-Silica columns, when used with acidic additives such as acetic acid or formic acid, are fundamental normal-phase columns that are expected to yield significant results in various fields such as natural product chemistry and organic synthesis chemistry.

CAUTION

UK-Silica is a pure silica column. While silica is extremely robust under acidic conditions, it is prone to dissolution in neutral pH environments such as ammonium acetate, which raises concerns about column bleeding and durability in LC-MS applications.

When using silica columns with aqueous mobile phases containing neutral salts like ammonium acetate or ammonium formate, it is recommended to keep the mixture ratio below 20% (preferably below 10%) to avoid silica hydrolysis.

User Articles

The sialyl-Tn antigen synthase genes regulates migration-proliferation dichotomy in prostate cancer cells under hypoxia


Phosphatidylinositol 4,5-bisphosphate-specific phospholipase C β1 selectively binds dipalmitoyl and distearoyl phosphatidic acids via Lys946 and Lys951


In vitro synthesis of mucin-type O-glycans using saccharide primers comprising GalNAc-Ser and GalNAc-Thr residues


Establishment to measure oxycodone in plasma with liquid chromatography-tandem mass spectrometry


Neuroprotective and Anti-Microglial Activation Effects of Tocotrienols in Brains of Lipopolysaccharide-Induced Inflammatory Model Mice


Heterogeneous Ganglioside-Enriched Nanoclusters with Different Densities in Membrane Rafts Detected by a Peptidyl Molecular Probe


EFFECT OF COMBINATION MICROWAVE AND OVEN DRYING ON THE CHEMICAL PROPERTIES OF DIFFERENT RIPENESS CRUDE PALM OIL


Determination of lamotrigine in human plasma using liquidchromatography-tandem mass spectrometry


Cytotoxicity and cellular uptake of perfluorodecanoic acid


Responsibility of lipid compositions for the amyloid ß assembly induced by ganglioside nanoclusters in mouse synaptosomal membranes


Identifcation of 14-dehydroergosterol as a novel anti-infammatory compound inducing tolerogenic dendritic cells


Assays for Methamphetamine and Amphetamine in Blood


Terpenoids, Flavonoids and Acetogenins from Some Malagasy Plants


A novel diacylglycerol kinase α-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response


SPIN TIP SOLID-PHASE EXTRACTION AND HILIC-MS-MS FOR QUANTITATIVE DETERMINATION OF METHAMPHETAMINE AND AMPHETAMINE IN HUMAN PLASMA


Diacylglycerol kinase-dependent formation of phosphatidic acid molecular species during interleukin-2 activation in CTLL-2 T-lymphocytes


Accelerated biosynthesis of neolacto-series glycosphingolipids in differentiated mouse embryonal carcinoma F9 cells detected by using dodecyl N-acetylglucosaminide as a saccharide primer


Pharmacological Profile of the Novel Anti-inflammatory Corticosteroid NS-126, a Therapeutic Agent for Allergic Rhinitis


Automatic Supported Liquid Extraction (SLE) Coupled with HILIC-MS/MS: An Application to Method Development and Validation of Erlotinib in Human Plasma